http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 17:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Jul+13/26785000.html si-local-file:///var/storage/secattach/20260717/26785000.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Jul+13/26785000.html Fri, 17 Jul 2026 17:00:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Jul+13/26785000.html si-local-file:///var/storage/secattach/20260717/26785000.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+Jul+13/26785000.html Fri, 17 Jul 2026 17:00:00 -0400 NKGN O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Press+Releases/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html <p align="justify">SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.</p> <p><strong>NKGen Presentation Details</strong><strong>:</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;"><strong>Title</strong>:<strong> </strong></td><td style="max-width:80%; width:80%; min-width:80%;">Use of Troculeucel (Cryopreserved Enhanced Autologous NK http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+to+Present+at+the+2026+BIOCHINA+Global+Forum+on+Troculeucel%E2%80%99s+Potential+in+Alzheimer%E2%80%99s+Disease+and+Other+Neurodegenerative+Conditions/26724247.html Thu, 02 Jul 2026 08:05:00 -0400 A.17568957 NKGN O.04889877 O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html si-local-file:///var/storage/secattach/20260602/26593274.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html Tue, 02 Jun 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html si-local-file:///var/storage/secattach/20260602/26593274.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+27/26593274.html Tue, 02 Jun 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html si-local-file:///var/storage/secattach/20260521/26536907.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html Thu, 21 May 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html si-local-file:///var/storage/secattach/20260521/26536907.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NKGen+Biotech%2C+Inc.+++++++For%3A+May+15/26536907.html Thu, 21 May 2026 17:20:00 -0400 NKGN O.50689666 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Press+Releases/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537 http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html <p><em>New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.</em></p> <p align="justify">SANTA ANA, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease.</p> <p align="justify">The new http://www.streetinsider.com/Globe+Newswire/NKGen+Biotech+Expands+Clinical+Trial+Site+Network+for+Alzheimer%E2%80%99s+Disease+Program+Across+U.S.+to+Improve+Patient+Access+and+Support+Enrollment/26517698.html Tue, 19 May 2026 08:05:00 -0400 A.17568957 A.50216777 NKGN O.04889877 O.50689666 O.54516537